- Home
- TGNA vs DYN Comparison
TGNA vs DYN Comparison
Compare TGNA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGNA
- DYN
- Stock Information
- Founded
- TGNA 1906
- DYN 1984
- Country
- TGNA United States
- DYN United States
- Employees
- TGNA N/A
- DYN N/A
- Industry
- TGNA Broadcasting
- DYN Medicinal Chemicals and Botanical Products
- Sector
- TGNA Industrials
- DYN Health Care
- Exchange
- TGNA Nasdaq
- DYN Nasdaq
- Market Cap
- TGNA 2.9B
- DYN 2.6B
- IPO Year
- TGNA N/A
- DYN 2020
- Fundamental
- Price
- TGNA $17.84
- DYN $14.01
- Analyst Decision
- TGNA Strong Buy
- DYN Strong Buy
- Analyst Count
- TGNA 4
- DYN 10
- Target Price
- TGNA $21.75
- DYN $50.78
- AVG Volume (30 Days)
- TGNA 993.2K
- DYN 2.1M
- Earning Date
- TGNA 02-27-2025
- DYN 03-04-2025
- Dividend Yield
- TGNA 2.80%
- DYN N/A
- EPS Growth
- TGNA N/A
- DYN N/A
- EPS
- TGNA 2.81
- DYN N/A
- Revenue
- TGNA $2,957,296,000.00
- DYN N/A
- Revenue This Year
- TGNA $8.69
- DYN N/A
- Revenue Next Year
- TGNA N/A
- DYN N/A
- P/E Ratio
- TGNA $6.35
- DYN N/A
- Revenue Growth
- TGNA N/A
- DYN N/A
- 52 Week Low
- TGNA $12.35
- DYN $13.07
- 52 Week High
- TGNA $19.62
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- TGNA 41.43
- DYN 37.85
- Support Level
- TGNA $17.81
- DYN $13.59
- Resistance Level
- TGNA $18.38
- DYN $14.50
- Average True Range (ATR)
- TGNA 0.35
- DYN 0.98
- MACD
- TGNA -0.03
- DYN 0.32
- Stochastic Oscillator
- TGNA 12.90
- DYN 22.90
About TGNA TEGNA Inc
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.